CollaborationAlfasigma SpA signs €170m deal with Galapagos NVLatest NewsFollowing its announcement from Oktober 2023 to take over the filgotinib business from Galapagos NV, Bologna-based Alfasigma SpA has signed the €170m deal. Read more 2 January 2024 https://european-biotechnology.com/wp-content/uploads/2024/04/Alfasigma_1-24.jpg 168 300 Thomas Gabrielczyk /wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png Thomas Gabrielczyk2024-01-02 08:39:562024-07-09 12:28:33Alfasigma SpA signs €170m deal with Galapagos NV